Comments on ‘Sentinel Lymph Node Mapping with Isosulfan Blue or Indocyanine Green in Colon Cancer Shows Comparable Results and Identifies Patients with Decreased Survival: A Prospective Single-Center Trial’
First, I want to congratulate the authors for their excellent work comparing two techniques for the detection of sentinel lymph nodes (SLN) in colon cancer . Weixler et al. compare the standard ‘blue dye’ technique using Isosulfan blue with a ‘fluorescence imaging technique using a non-specific fluorophore.’ However, we are concerned that the authors fail to distinguish the differences between ‘indocyanine green fluorescence imaging’ (ICG-FI) and fluorescence imaging (FI) with the IRDye 800CW fluorophore used in their study. There is no correlation between these two molecules apart from the fact that both are used as ‘fluorescent probes’ in the near infrared (NIR) spectrum for FI. In fact, as mentioned in the paper by the authors, IRDye 800CW is not FDA approved for ‘in vivo’ human use. Conversely, ICG has been FDA approved since the early 1960s and is recognized as a safe NIR probe for clinical use in several indications. The main indication is being its use as contrast agent after intravenous injection [2, 3]. By using the same term for these two different dyes, the results presented in this study may be confused with those of our published study comparing the standard ex vivo blue dye technique using patent blue with ICG-FI (not cited in Weixler et al. 2017) . Finally, the authors also argue that HSA800, a combination of human serum albumin and IRDye 800 CW, contains indocyanine green at a ratio of 1:3 (ICG:Albumin). This is incorrect as HSA800 contains only IRDye 800CW at a ratio of 1:3 (IRDye 800CW:Albumin).
Therefore, in an effort to avoid confusion for the scientific community, we believe it is important to point out these important inconsistencies in terminology.
- 1.Weixler B, Rickenbacher A, Raptis DA et al (2017) Sentinel lymph node mapping with isosulfan blue or indocyanine green in colon cancer shows comparable results and identifies patients with decreased survival: a prospective single-center trial. World J Surg 41:2378–2386. https://doi.org/10.1007/s00268-017-4051-2 CrossRefPubMedGoogle Scholar